Production (Stage)
Black Diamond Therapeutics, Inc.
BDTX
$1.99
-$0.06-2.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.00M | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 70.00M | -- | -- | -- | -- |
| SG&A Expenses | 4.96M | 3.03M | 5.22M | 9.57M | 6.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.47M | 15.33M | 18.13M | 22.13M | 20.25M |
| Operating Income | 54.53M | -15.33M | -18.13M | -22.13M | -20.25M |
| Income Before Tax | 56.54M | -15.99M | -15.56M | -19.91M | -18.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.54M | -15.99M | -15.56M | -19.91M | -18.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.54M | -15.99M | -15.56M | -19.91M | -18.23M |
| EBIT | 54.53M | -15.33M | -18.13M | -22.13M | -20.25M |
| EBITDA | 54.62M | -15.25M | -18.04M | -22.04M | -20.16M |
| EPS Basic | 1.00 | -0.28 | -0.28 | -0.36 | -0.35 |
| Normalized Basic EPS | 0.62 | -0.15 | -0.17 | -0.23 | -0.23 |
| EPS Diluted | 0.98 | -0.28 | -0.28 | -0.36 | -0.35 |
| Normalized Diluted EPS | 0.61 | -0.15 | -0.17 | -0.23 | -0.23 |
| Average Basic Shares Outstanding | 56.66M | 56.61M | 56.51M | 55.16M | 51.81M |
| Average Diluted Shares Outstanding | 57.67M | 56.61M | 56.51M | 55.16M | 51.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |